Group 1 - Company X has entered into a placement agreement to issue 55 million shares, representing approximately 3.33% of its total issued shares as of the announcement date [1][2] - The placement price is set at HKD 82.4 per share, reflecting a discount of about 4.90% from the closing price on June 25 [2] - The expected total proceeds from the placement are approximately HKD 4.31 billion, with a net amount of about HKD 4.265 billion after costs [2] Group 2 - Approximately 90% of the net proceeds (around HKD 3.839 billion) will be allocated to the global research and development of key innovative pipelines and global facility layout [2] - The remaining 10% (approximately HKD 427 million) will be used for the company's daily operations [2] Group 3 - The recent trend shows a recovery in the financing environment for innovative drugs, with several leading pharmaceutical companies, including Company X, actively pursuing new share placements and financing initiatives [1][4] - Company Y has also completed a new H-share placement, raising approximately HKD 1.039 billion, with 70% of the funds earmarked for innovative drug research [3] Group 4 - The primary market for investment and financing has shown signs of recovery after a period of tightening, with business development transactions becoming a core growth logic for innovative drugs in China [4] - The recent successful IPO of Company Z and the upcoming listing of Wuhan Heyuan Biotechnology Co., Ltd. indicate a thawing in the A-share market for pharmaceutical companies [4][5]
信达生物折价配股募资约43亿港元 近期多家头部药企再融资动作频频